Cargando…

Comment on ‘The efficacy and toxicity of gemcitabine, carboplatin and bevacizumab in metastatic breast cancer‘

Detalles Bibliográficos
Autores principales:	Kitchen, D, O'Brien, M, Hughes, B, Gill, I, Rumbles, S, Ellis, P, Stebbing, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3721388/ https://www.ncbi.nlm.nih.gov/pubmed/23756861 http://dx.doi.org/10.1038/bjc.2013.279

Ejemplares similares

The relationship between vitamin D and chemotherapy-induced toxicity – a pilot study
por: Kitchen, D, et al.
Publicado: (2012)

Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity
por: Helbekkmo, N, et al.
Publicado: (2007)

Bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer: a critical consideration
por: Giovannoni, Sara, et al.
Publicado: (2014)

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
por: Yardley, D A, et al.
Publicado: (2018)

Comment on ‘Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer’
por: Molina-Garrido, M J, et al.
Publicado: (2011)

A case of recurrent malignant fibrous histiocytoma with marked response to combined chemotherapy with gemcitabine and carboplatin
por: Wei, Zhang, et al.
Publicado: (2014)

Improvement of Breast Cancer-Associated Pulmonary Tumor Thrombotic Microangiopathy With Carboplatin and Gemcitabine
por: Tran, Helen, et al.
Publicado: (2023)

Comment on: ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'
por: Vivaldi, Caterina, et al.
Publicado: (2016)

Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases
por: Leone, Jose Pablo, et al.
Publicado: (2020)

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial
por: Yardley, Denise A., et al.
Publicado: (2015)

Comment on: Role of subconjunctival bevacizumab in primary pterygium surgery
por: Shivalli, Siddharudha, et al.
Publicado: (2016)

Comment on: Dramatic response to intravitreal bevacizumab in hypertensive retinopathy
por: Samanta, Ramanuj
Publicado: (2019)

Comment on: Dramatic response to intravitreal bevacizumab in hypertensive retinopathy
por: Tripathy, Koushik, et al.
Publicado: (2019)

Comment on “bevacizumab or laser for aggressive posterior retinopathy of prematurity”
por: Samanta, Ramanuj
Publicado: (2019)

Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial
por: Yardley, Denise A., et al.
Publicado: (2016)

Reply to the comment on ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'
por: Pernot, Simon, et al.
Publicado: (2016)

Bevacizumab-Induced Thrombotic Microangiopathy (TMA) in Metastatic Lung Adenocarcinoma Patients Receiving Nivolumab Combined with Bevacizumab, Carboplatin and Paclitaxel: Two Case Reports
por: Hsu, Ping-Chih, et al.
Publicado: (2023)

Response to comment on: Dramatic response to intravitreal bevacizumab in hypertensive retinopathy
por: Padhi, Srikant, et al.
Publicado: (2019)

Response to comment on: Dramatic response to intravitreal Bevacizumab in hypertensive retinopathy
por: Padhi, Srikant, et al.
Publicado: (2019)

The association of four genetic variants with myelosuppression in gemcitabine‐treated Japanese is not evident in gemcitabine/carboplatin‐treated Swedes
por: Björn, Niclas, et al.
Publicado: (2022)

Efficacy of paclitaxel, carboplatin, and bevacizumab for cervical cancer: A protocol for systematic review and meta-analysis
por: Zhang, Li, et al.
Publicado: (2020)

Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer
por: Wan, Guoxing, et al.
Publicado: (2019)

Randomized Phase II Study of First‐Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non‐Small Cell Lung Cancer: LOGIK0801
por: Takayama, Koichi, et al.
Publicado: (2020)

Outcome and toxicity of ifosfamide, carboplatin, and etoposide versus gemcitabine and vinorelbine regimen for pediatric patients with relapsed or refractory Hodgkin’s lymphoma
por: Mahdy, Ahmed, et al.
Publicado: (2023)

Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
por: Sugimoto, Kazuma, et al.
Publicado: (2022)

A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung
por: Yang, Jin-Ji, et al.
Publicado: (2014)

Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer
por: Minami, Seigo, et al.
Publicado: (2013)

DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2018)

Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma
por: Galvão, Flávio Henrique Ferreira, et al.
Publicado: (2009)

Haematological toxicity of carboplatin in rats.
por: Siddik, Z. H., et al.
Publicado: (1987)

Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'
por: Imafuku, Keisuke, et al.
Publicado: (2017)

Long-Term Complete Remission with nab-Paclitaxel, Bevacizumab, and Gemcitabine Combination Therapy in a Patient with Triple-Negative Metastatic Breast Cancer
por: Montero, Alberto, et al.
Publicado: (2012)

Successful Treatment with Pemetrexed, Carboplatin, and Bevacizumab for Platinum-Resistant Adenocarcinoma of the Lung
por: Wada, Sae, et al.
Publicado: (2012)

Pulmonary toxicity in patients treated with gemcitabine and a combination of gemcitabine and a taxane: investigation of a signal using postmarketing data
por: Czarnecki, A, et al.
Publicado: (2006)

Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''
por: Bowyer, Samantha, et al.
Publicado: (2017)

Efficacy of Bevacizumab-Capecitabine in Combination for the First-Line Treatment of Metastatic Breast Cancer
por: Dyar, Stephen, et al.
Publicado: (2011)

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2023)

Comment on ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’
por: Charbonneau, C, et al.
Publicado: (2010)

Efficacy of Bevacizumab and Gemcitabine in Combination with Cisplatin in the Treatment of Esophageal Cancer and the Effect on the Incidence of Adverse Reactions
por: Wang, Jiangfeng, et al.
Publicado: (2022)

A Case of Biphasic Pulmonary Blastoma Treated with Carboplatin and Paclitaxel plus Bevacizumab
por: Sakata, Shinya, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_of60vfmqddi2553rs7he5e5jko